Meanwhile, the median [95% confidence interval (CI)] DFS of patients with high tumor PLK5 protein expression was 48.0 (34.7–61.3) months, with a 3-year DFS rate of 64.7% and a 5-year DFS rate of 32.2%; for patients with low tumor PLK5 protein expression, the median (95% CI) DFS was 34.0 (30.5–37.5) months, with a 3-year DFS rate of 46.6% and a 5-year DFS rate of 11.3% in NSCLC patients (Figure 2A). This evidence concerns the gene PLK5 and neoplasm.